Who Paid My Doc
Pradeep Nair
Interventional Cardiology Houma, LA Medical Doctor
NPI 1659517670 CMS profile 211253
225 Dunn St, Houma, LA 70360
General payments
$212,371
Research payments
$4,200
Ownership & investment interest
$25,000
Research they led as principal investigator
$8,000
Through program year 2025, Pradeep Nair of Houma, LA is reported in the CMS Open Payments database as having received $212,371 across 498 general payments and $4,200 in research payments paid to them. Separately, studies naming them as principal investigator received $8,000 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $25,000 across 1 holding.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 96th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
9 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $55,673 | 112 | |
| 2024 | General | $51,519 | 105 | |
| 2023 | General | $61,557 | 104 | |
| 2022 | General | $12,464 | 63 | |
| 2022 | Research | $4,200 | 1 | |
| 2021 | General | $22,232 | 51 | |
| 2020 | General | $6,770 | 32 | |
| 2019 | General | $2,157 | 31 | |
| 2024 | Ownership | $25,000 | 1 |
Beside peers
- Pradeep Nair
- Interventional Cardiology median
- Middle half of Interventional Cardiology
- National median
In program year 2025, general payments to Pradeep Nair were reported at $55,673. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.
Show as a table
| Year | Pradeep Nair | Interventional Cardiology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $2,157 | $1,097 | $329–$3,048 | $163 |
| 2020 | $6,770 | $473 | $161–$1,480 | $114 |
| 2021 | $22,232 | $677 | $233–$1,827 | $132 |
| 2022 | $12,464 | $978 | $333–$2,724 | $149 |
| 2023 | $61,557 | $1,136 | $382–$2,986 | $160 |
| 2024 | $51,519 | $1,181 | $395–$3,326 | $164 |
| 2025 | $55,673 | $1,092 | $366–$3,019 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 67 drugsPart D claims
7,681
Drug cost
$1,238,849
Branded share of claims
33.9%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 342 | $335,376 | |
| Vyndamax Tafamidis | Brand | 11 | $285,696 | |
| Xarelto Rivaroxaban | Brand | 386 | $275,118 | |
| Repatha Sureclick Evolocumab | Brand | 125 | $90,320 | |
| Brilinta Ticagrelor | Brand | 110 | $69,615 | |
| Entresto Sacubitril/Valsartan | Brand | 43 | $44,379 | |
| Jardiance Empagliflozin | Brand | 19 | $21,699 | |
| Praluent Pen Alirocumab | Brand | 32 | $17,146 | |
| Farxiga Dapagliflozin Propanediol | Brand | 15 | $14,093 | |
| Clopidogrel Clopidogrel Bisulfate | Brand | 1,012 | $10,245 |
The 10 drugs with the highest cost, of 67 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 163 billing codesPaid by Medicare
$558,433
Medicare patients
783
Services billed
5,481
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Ischemic heart disease | 63% | |
| Arthritis | 52% | |
| Diabetes | 43% | |
| Heart failure | 37% | |
| Atrial fibrillation | 34% | |
| Chronic kidney disease | 32% | |
| COPD | 30% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, regadenoson, 0.1 mg J2785 | Office | 30 | 120 | $592 |
| Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 | Office | 21 | 28 | $140 |
| Injection, methylprednisolone acetate, 1 mg J1010 | Office | 13 | 23 | $2 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
499 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Interventional Cardiology in Louisiana
Practitioners in the same specialty and state, ranked by reported value.
All Interventional Cardiology
Everyone recorded under this specialty, nationwide.
Doctors in Louisiana
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.